The science of slowed gastrointestinal motility GLP-1 receptor agonists act on the gutbrain axis and are known to slow gastric emptying and overall gastrointestinal transit , contributing to early satiety and appetite suppression. As intestinal transit slows, the colon has more time to absorb water from stool , leading to hard, dry stools that are difficult to pass . Constipation is a common, dose-related adverse effect listed in FDA prescribing information for both Wegovy (semaglutide) and Zepbound (tirzepatide) and is most frequently reported during dose escalation , with improvement over time., Step-by-Step MD Protocol for Relief 1
Four weeks of weekly doses at 2.5mg fits perfectly within that window
The incidence of obesity worldwide has more than doubled since the 1990 s, increasing the risk of type 2 diabetes (T2DM), cardiovascular complications and cancer
If you like this article, please like/share, and thank you
doi: 10.1152/ajpcell.00654.2023 117 QianFHuoD
Vegan, Non-GMO, Third-Party Tested